A multicenter randomized Phase III trial of enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer

Trial Profile

A multicenter randomized Phase III trial of enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Enzalutamide (Primary) ; Abiraterone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms Enable
  • Most Recent Events

    • 05 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top